Transdermal delivery systems, such as patches. for certain direct factor Xa inhibitors (“FXa”), as well as methods for the manufacture and use of such transdermal patches. particularly in the treatment of thrombosis or in other conditions wherein an anticoagulant is desired. and to prevent stroke and embolism in people with atrial fibrillation (AF).
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Drug delivery agents in the form of dissolvable or erodible films that facilitate the oral, transmucosal or transdermal delivery of pharmaceutical preparations; drug delivery agents in the form of transdermal patches, oral thin films, topical gels, creams, ointments, and oral liquids that facilitate the delivery of pharmaceutical preparations Custom manufacture of pharmaceuticals; Custom of manufacture of drug delivery systems; Custom manufacture of oral dissolvable films; Custom manufacture of erodible films; Custom manufacture of transdermal patches; Custom manufacture of topical gels, creams or ointments, and oral liquids Oral thin films and transdermal drug delivery patches sold without medication Research and development services in the field of pharmaceutical preparations; Research and development in the field of drug delivery systems comprising dissolvable films, erodible films or transdermal patches, topical gels, creams or ointments, and oral liquids, containing pharmaceutically active ingredients for the release of a wide variety of therapeutic agents
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Drug delivery agents in the form of dissolvable or erodible films that facilitate the oral, transmucosal or transdermal delivery of pharmaceutical preparations; drug delivery agents in the form of transdermal patches, oral thin films, topical gels, creams, ointments, and oral liquids that facilitate the delivery of pharmaceutical preparations Custom manufacture of pharmaceuticals; Custom of manufacture of drug delivery systems; Custom manufacture of oral dissolvable films; Custom manufacture of erodible films; Custom manufacture of transdermal patches; Custom manufacture of topical gels, creams or ointments, and oral liquids Oral thin films and transdermal drug delivery patches sold without medication Research and development services in the field of pharmaceutical preparations; Research and development in the field of drug delivery systems comprising dissolvable films, erodible films or transdermal patches, topical gels, creams or ointments, and oral liquids, containing pharmaceutically active ingredients for the release of a wide variety of therapeutic agents
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Transdermal delivery systems, such as patches, for certain direct factor Xa inhibitors ("FXa"), as well as methods for the manufacture and use of such transdermal patches, particularly in the treatment of thrombosis or in other conditions wherein an anticoagulant is desired, and to prevent stroke and embolism in people with atrial fibrillation (AF).
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier. The method further includes depositing the composition for the active layer onto the muco-adhesive substrate as a plurality of individual volumes and removing the liquid carrier from the plurality of deposited individual volumes to form a plurality of dissolvable film active layers on the muco-adhesive substrate.
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier. The method further includes depositing the composition for the active layer onto the muco-adhesive substrate as a plurality of individual volumes and removing the liquid carrier from the plurality of deposited individual volumes to form a plurality of dissolvable film active layers on the muco-adhesive substrate.
Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier. The method further includes depositing the composition for the active layer onto the muco-adhesive substrate as a plurality of individual volumes and removing the liquid carrier from the plurality of deposited individual volumes to form a plurality of dissolvable film active layers on the muco-adhesive substrate.
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
A method of forming a kit containing multiple dissolvable unit dose constructs includes providing at least one muco-adhesive composition comprising a polymer matrix, the polymer matrix comprising a water soluble polymer, an active ingredient and a liquid carrier; forming a plurality of dissolvable thin film unit dose constructs by depositing the at least one composition onto a substrate wherein at least two adjacent dissolvable thin film unit dose constructs are formed having a pre-determined different identifiable physical characteristic with respect to the other as a result of the depositing; and packaging the plurality of dissolvable thin films in a single package to form a kit.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.
Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A method of forming a liquid formulation includes preparing a mixture and adding a second component to the mixture to form the liquid formulation. The mixture includes water, a film- forming polymer, a buffer, and a first component. The first component is an active ingredient including buprenorphine or a sweetener. The second component is the active ingredient comprising buprenorphine or the sweetener. Adding the second component is the last step in creating the liquid formulation. If the first component is the active ingredient, the second component is the sweetener. If the first component is the sweetener, the second component is the active ingredient. A method of forming a water-disintegrable film includes casting a formulation film from the liquid formulation and drying the formulation film to form the water-disintegrable film. A film formulation and a water-disintegrable film are also disclosed.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.
Dissolvable unit dose constructs and their method of manufacture are disclosed in which the unit dose constructs are formed of a composition including a polymer matrix that includes a water soluble polymer, active ingredient, and a liquid carrier. The composition is deposited directly, such as by stenciling, to form individual unit doses without the need to cut and convert long, continuous rolls of film.
The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
